Cargando…

A First‐in‐Human Phase I Study of GC1118, a Novel Anti‐Epidermal Growth Factor Receptor Antibody, in Patients with Advanced Solid Tumors

LESSONS LEARNED. GC1118 is a novel fully human anti‐epidermal growth factor receptor (EGFR) antibody with unique binding epitopes and different ligand‐binding inhibitory activity compared with cetuximab or panitumumab. GC1118 showed promising antitumor activity, especially in patients with colorecta...

Descripción completa

Detalles Bibliográficos
Autores principales:	Oh, Do‐Youn, Lee, Keun‐Wook, Han, Sae‐Won, Kim, Jin Won, Shin, Jung‐Won, Jo, Seong‐Jin, Won, Jonghwa, Hahn, Seokyung, Lee, Howard, Kim, Woo Ho, Bang, Yung‐Jue
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2019
Materias:	Clinical Trial Results
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6693725/ https://www.ncbi.nlm.nih.gov/pubmed/31164456 http://dx.doi.org/10.1634/theoncologist.2019-0294

Ejemplares similares

Phase I Pharmacokinetic Study of Nivolumab in Korean Patients with Advanced Solid Tumors
por: Lee, Keun‐Wook, et al.
Publicado: (2017)

A target‐mediated drug disposition population pharmacokinetic model of GC1118, a novel anti‐EGFR antibody, in patients with solid tumors
por: Chung, Tae Kyu, et al.
Publicado: (2021)

A Phase II Study of Genexol‐PM and Cisplatin as Induction Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma
por: Keam, Bhumsuk, et al.
Publicado: (2019)

A Phase III Study to Compare the Efficacy and Safety of Paclitaxel Versus Irinotecan in Patients with Metastatic or Recurrent Gastric Cancer Who Failed in First‐line Therapy (KCSG ST10‐01)
por: Lee, Keun‐Wook, et al.
Publicado: (2018)

AZD8186 in Combination With Paclitaxel in Patients With Advanced Gastric Cancer: Results From a Phase Ib/II Study (KCSG ST18-20)
por: Suh, Koung Jin, et al.
Publicado: (2023)

Impact of dementia and drug compliance on patients with acute myocardial infarction
por: Lee, Wonjae, et al.
Publicado: (2023)

A Phase I/IIa Study of DHP107, a Novel Oral Paclitaxel Formulation, in Patients with Advanced Solid Tumors or Gastric Cancer
por: Ryu, Min‐Hee, et al.
Publicado: (2017)

A Phase I Study of Abiraterone Acetate Combined with BEZ235, a Dual PI3K/mTOR Inhibitor, in Metastatic Castration Resistant Prostate Cancer
por: Wei, Xiao X., et al.
Publicado: (2017)

Phase I Dose‐Escalation Study of Ramucirumab in Chinese Patients with Advanced Solid Tumors
por: Cao, Junning, et al.
Publicado: (2017)

A Phase II Trial of Selinexor, an Oral Selective Inhibitor of Nuclear Export Compound, in Abiraterone‐ and/or Enzalutamide‐Refractory Metastatic Castration‐Resistant Prostate Cancer
por: Wei, Xiao X., et al.
Publicado: (2018)

Electrocardiographic Characterization of Ramucirumab on the Corrected QT Interval in a Phase II Study of Patients With Advanced Solid Tumors
por: Olszanski, Anthony J., et al.
Publicado: (2016)

Therapeutic Efficacy of GC1118, a Novel Anti-EGFR Antibody, against Glioblastoma with High EGFR Amplification in Patient-Derived Xenografts
por: Lee, Kyoungmin, et al.
Publicado: (2020)

Phase I, First‐in‐Human, Dose‐Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Vorolanib in Patients with Advanced Solid Tumors
por: Bendell, Johanna C., et al.
Publicado: (2018)

Epacadostat Plus Pembrolizumab and Chemotherapy for Advanced Solid Tumors: Results from the Phase I/II ECHO-207/KEYNOTE-723 Study
por: Powderly, John D, et al.
Publicado: (2022)

A multicenter, phase II trial of GC1118, a novel anti‐EGFR antibody, for recurrent glioblastoma patients with EGFR amplification
por: Choi, Seung Won, et al.
Publicado: (2023)

Adapalene Gel 0.1% Versus Placebo as Prophylaxis for Anti‐Epidermal Growth Factor Receptor‐Induced Acne‐Like Rash: A Randomized Left‐Right Comparative Evaluation (APPEARANCE)
por: Chayahara, Naoko, et al.
Publicado: (2019)

Promising Therapeutic Efficacy of GC1118, an Anti-EGFR Antibody, against KRAS Mutation-Driven Colorectal Cancer Patient-Derived Xenografts
por: Lee, Hye Won, et al.
Publicado: (2019)

Osimertinib in Elderly Patients with Epidermal Growth Factor Receptor T790M‐Positive Non‐Small‐Cell Lung Cancer Who Progressed During Prior Treatment: A Phase II Trial
por: Nakao, Akira, et al.
Publicado: (2019)

Phase Ia/Ib Study of the Selective MET Inhibitor, Savolitinib, in Patients with Advanced Solid Tumors:  Safety, Efficacy, and Biomarkers
por: Wang, Yakun, et al.
Publicado: (2022)

Phase I Study of JNJ-74699157 in Patients with Advanced Solid Tumors Harboring the KRAS G12C Mutation
por: Wang, Judy, et al.
Publicado: (2022)

A Phase II Trial of Pazopanib in Patients with Metastatic Alveolar Soft Part Sarcoma
por: Kim, Miso, et al.
Publicado: (2018)

A Phase Ib/II Study of the JAK1 Inhibitor, Itacitinib, plus nab‐Paclitaxel and Gemcitabine in Advanced Solid Tumors
por: Beatty, Gregory L., et al.
Publicado: (2018)

Phase I Dose‐Escalation Study of Pilaralisib (SAR245408, XL147) in Combination with Paclitaxel and Carboplatin in Patients with Solid Tumors
por: Wheler, Jennifer, et al.
Publicado: (2017)

A Phase Ib Study of Axitinib in Combination with Crizotinib in Patients with Metastatic Renal Cell Cancer or Other Advanced Solid Tumors
por: Michaelson, M. Dror, et al.
Publicado: (2019)

A Phase I/II Open‐Label Study of Nivolumab in Previously Treated Advanced or Recurrent Nasopharyngeal Carcinoma and Other Solid Tumors
por: Ma, Yuxiang, et al.
Publicado: (2019)

Selection of Protein Kinase Inhibitors Based on Tumor Tissue Kinase Activity Profiles in Patients with Refractory Solid Malignancies: An Interventional Molecular Profiling Study
por: Labots, Mariette, et al.
Publicado: (2018)

Phase I Trial of a Tablet Formulation of Pilaralisib, a Pan‐Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors
por: Edelman, Gerald, et al.
Publicado: (2018)

A Phase I Open‐Label Clinical Trial Evaluating the Therapeutic Vaccine hVEGF26–104/RFASE in Patients with Advanced Solid Malignancies
por: Goedegebuure, Ruben S.A., et al.
Publicado: (2020)

Phase I Study of the Bifunctional Fusion Protein Bintrafusp Alfa in Asian Patients with Advanced Solid Tumors, Including a Hepatocellular Carcinoma Safety‐Assessment Cohort
por: Doi, Toshihiko, et al.
Publicado: (2020)

Phase I Study of Lenvatinib and Capecitabine with External Radiation Therapy in Locally Advanced Rectal Adenocarcinoma
por: Mehta, Rutika, et al.
Publicado: (2022)

Atezolizumab Plus PEGPH20 Versus Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma and Gastric Cancer: MORPHEUS Phase Ib/II Umbrella Randomized Study Platform
por: Ko, Andrew H, et al.
Publicado: (2023)

Single Arm, Phase II Study of Cisplatin, Docetaxel, and Erlotinib in Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinomas
por: William, William N., et al.
Publicado: (2018)

Three-Year Outcomes of a Phase II Study of Perioperative Capecitabine Plus Oxaliplatin Therapy for Clinical SS/SE N1-3 M0 Gastric Cancer (OGSG 1601)
por: Matsuyama, Jin, et al.
Publicado: (2022)

A Phase II Clinical Trial on the Combination Therapy of PHY906 Plus Capecitabine in Hepatocellular Carcinoma
por: Changou, Chun A., et al.
Publicado: (2020)

Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open‐Label, Phase I Trial (JVDF)
por: Arkenau, Hendrik‐Tobias, et al.
Publicado: (2018)

A Phase Ib Dose-Escalation Study of LCL161 Plus Oral Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies
por: Johnson, Melissa L, et al.
Publicado: (2023)

Docetaxel, Oxaliplatin, and 5‐Fluorouracil (DOF) in Metastatic and Unresectable Gastric/Gastroesophageal Junction Adenocarcinoma: A Phase II Study with Long‐Term Follow‐Up
por: Rosenberg, Ari Joseph, et al.
Publicado: (2019)

Phase II Clinical and Translational Study of Everolimus ± Paclitaxel as First-Line Therapy in Cisplatin-Ineligible Advanced Urothelial Carcinoma
por: Jun, Tomi, et al.
Publicado: (2022)

A Phase II Trial of a Histone Deacetylase Inhibitor Panobinostat in Patients With Low-Grade Neuroendocrine Tumors
por: Jin, Ning, et al.
Publicado: (2016)

Phase II Trial of Sorafenib in Combination with Capecitabine in Patients with Hepatocellular Carcinoma: INST 08‐20
por: Patt, Yehuda, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_j10fpmgch6ke9t5to3l5nj23gc